PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 20, 2021JAMA Cardiology188 citationsOpen Access

Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction

View Full Paper
DBDavid D. BergPJPardeep S. JhundKDKieran F. Docherty

Key Points

  • To assess the time to clinical benefit of dapagliflozin in patients with heart failure with reduced ejection fraction and the role of prior hospitalization due to heart failure.
  • Randomized controlled trial design
  • Inclusion of patients with reduced ejection fraction
  • Administration of dapagliflozin
  • Assessment of clinical outcomes over time
  • Dapagliflozin showed a significant time to clinical benefit
  • Prior heart failure hospitalization influenced outcomes
  • Improvement in clinical markers of heart failure noted

Abstract

ClinicalTrials.gov Identifier NCT03036124.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Berg et al. (2021) studied this question. Dapagliflozin significantly shortened the time to clinical benefit in patients with heart failure with reduced ejection fraction compared to those with prior hospitalization for heart failure.

synapsesocial.com/papers/696910e587f73b5c2af0cedehttps://doi.org/10.1001/jamacardio.2020.7585
Ask AI
Helpful
Bookmark
Share
View Full Paper